Fairfield, Bush & Co. Vertex Pharmaceuticals Inc Transaction History
Fairfield, Bush & Co.
- $168 Billion
- Q3 2024
A detailed history of Fairfield, Bush & Co. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Fairfield, Bush & Co. holds 1,401 shares of VRTX stock, worth $572,672. This represents 0.39% of its overall portfolio holdings.
Number of Shares
1,401
Previous 1,846
24.11%
Holding current value
$572,672
Previous $865 Million
24.7%
% of portfolio
0.39%
Previous 0.52%
Shares
6 transactions
Others Institutions Holding VRTX
# of Institutions
1,724Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$11 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$9.47 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.71 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.83 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$3.68 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $105B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...